Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates and improved survival for patients with unresectable hepatocellular ...

That efficacy exceeded iTeos’ expectations and was backed by a safety profile “in line with the TIGIT:PD-1 class,” said the company. Protein degrader specialist Lycia Therapeutics completed ...

Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in small cell lung cancer (SCLC), in a blow to its ambitions in ...

Teos' Belrestotug shows efficacy in trials, backed by a strong cash runway. Learn why ITOS stock might thrive with strategic ...

Q4 2024 Earnings Call Transcript March 4, 2025 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.07 EPS, ...

Compugen Ltd (CGEN) showcases promising developments in oncology treatments while navigating a decrease in annual revenue and ...

Arcus Biosciences, Inc.’s RCUS share price has surged by 10.22%, which has investors questioning if this is right time to ...

Reports Q4 revenue $1.5M, consensus $17.47M. Expects current cash will be sufficient to fund its operating plans into 2027. “I believe Compugen ...

Compugen (NASDAQ:CGEN – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of $0.07 ...

Although immune checkpoint inhibitors have shown noticeable clinical benefits, tumor evasion of single-agent immunotherapy occurs in some patients due to the compensatory role of alternative immune ...